Step 5: Analysis of the data

LEO Pharma provides controlled access to the anonymised data. This implies that the analyses by the researchers shall be performed in a closed environment with the required analysis tools and computer programs available.

No download or printing of data is allowed. When the researchers have completed their analyses, the final output is exported from the system by LEO Pharma.

The analyses of data must be conducted according to what was approved by the Patient and Scientific Review Board. The conditions of the Data Sharing Agreement must be observed (see Step 4).

For data access support, contact the clinical trial disclosure mailbox (disclosure@leo-pharma.com).